Treatment of Erythroderma in Psoriasis

This protocol covers erythroderma occurring in patients with psoriasis — the most frequent underlying cause of generalised exfoliative dermatitis. Psoriasis accounts for a substantial proportion of erythroderma cases across published clinical series.

Systemic therapy is the cornerstone of first-line management. The evidence distinguishes agents by speed of onset: some are recognised for acting more rapidly, while others, though effective, tend to work more slowly. The appropriate choice depends on clinical urgency and patient-specific factors.

The complete structured regimen — including specific agent selection, sequencing, and monitoring guidance — is available in the full protocol below.